Andrew Dreyfus's most recent trade in Alto Neuroscience Inc. was a trade of 10,958 Stock Option (right to buy) done . Disclosure was reported to the exchange on May 12, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Alto Neuroscience Inc | Andrew Dreyfus | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2026 | 10,958 | 10,958 | - | - | Stock Option (right to buy) | |
| Ironwood Pharma Inc (Class A) | Andrew Dreyfus | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 45,000 | 228,313 (0%) | 0% | 0 | Class A Common Stock | |
| Alto Neuroscience Inc | Andrew Dreyfus | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2025 | 15,287 | 15,287 | - | - | Stock Option (right to buy) | |
| Ironwood Pharma Inc (Class A) | Andrew Dreyfus | Director | 18 Jun 2024 | 24,311 | 188,230 (0%) | 0% | 0 | Class A Common Stock | ||
| Alto Neuroscience Inc | Andrew Dreyfus | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 30,574 | 30,574 | - | - | Stock Option (right to buy) | |
| Ironwood Pharma Inc (Class A) | Andrew Dreyfus | Director | 20 Jun 2023 | 22,350 | 168,980 (0%) | 0% | 0 | Class A Common Stock | ||
| Ironwood Pharma Inc (Class A) | Andrew Dreyfus | Director | 01 Jun 2022 | 21,571 | 151,639 (0%) | 0% | 0 | Class A Common Stock | ||
| Ironwood Pharma Inc (Class A) | Andrew Dreyfus | Director | 15 Dec 2021 | 1,431 | 130,077 (0%) | 0% | 0 | Class A Common Stock | ||
| Ironwood Pharma Inc (Class A) | Andrew Dreyfus | Director | 15 Sep 2021 | 1,344 | 134,660 (0%) | 0% | 0 | Class A Common Stock |